Cargando…

Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors

BACKGROUND: This phase I, randomized, multicenter, open-label study investigated the pharmacokinetics, safety, and efficacy of the oral mammalian target of rapamycin inhibitor everolimus in Chinese patients with advanced solid tumors. METHODS: A total of 24 patients with advanced breast cancer (n =...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, BingHe, Wu, YiLong, Shen, Lin, Ye, DingWei, Jappe, Annette, Cherfi, Azzeddine, Wang, Hui, Yuan, RuiRong
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032760/ https://www.ncbi.nlm.nih.gov/pubmed/21232120 http://dx.doi.org/10.1186/1756-8722-4-3

Ejemplares similares

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors
por: Luo, Yang, et al.
Publicado: (2023)

Efficacy and Safety of [(177)Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literature Review
por: Hertelendi, Marianna, et al.
Publicado: (2023)

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
por: Deenen, Maarten J., et al.
Publicado: (2011)

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/−) Mice Is Superior to Everolimus Alone()
por: Yang, Jian, et al.
Publicado: (2017)

Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
por: Borgå, Olof, et al.
Publicado: (2019)

Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers
por: Liu, Jian, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers
por: Li, Yingxin, et al.
Publicado: (2023)

Safety, Tolerability and Pharmacokinetics of Single-Dose Oral SYHA1402 in Healthy Chinese Subjects
por: Liang, Beibei, et al.
Publicado: (2023)

Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
por: Guo, Jun, et al.
Publicado: (2013)

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
por: de Wit, D., et al.
Publicado: (2016)

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer
por: Pascual, Tomas, et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
por: He, Xuemei, et al.
Publicado: (2022)

Everolimus treatment in advanced solid tumors: a personal view
por: Pusceddu, Sara, et al.
Publicado: (2015)

A Multi-Centric Study Assessing Safety and Efficacy of Everolimus in Adult Chinese Patients With Tuberous Sclerosis Complex Associated Renal Angiomyolipomas
por: Wang, Wenda, et al.
Publicado: (2022)

Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer
por: Hirabatake, Masaki, et al.
Publicado: (2022)

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
por: Yonemori, Kan, et al.
Publicado: (2021)

Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing
por: Wicha, Wolfgang W, et al.
Publicado: (2019)

Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
por: Holdaas, Hallvard, et al.
Publicado: (2016)

Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study
por: Chen, Qian, et al.
Publicado: (2018)

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
por: Mo, Hongnan, et al.
Publicado: (2018)

Tolérance de l’évérolimus en pratique clinique: étude retrospective
por: Afani, Leila, et al.
Publicado: (2020)

The randomized, single‐ and multiple‐ ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects
por: Jing, Shan, et al.
Publicado: (2022)

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
por: Bendell, Johanna C., et al.
Publicado: (2018)

Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
por: Doi, Toshihiko, et al.
Publicado: (2020)

Multiple intracardiac benign tumors treated with low-dose everolimus
por: Beyazal, Meryem, et al.
Publicado: (2022)

Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study
por: Noreikaitė, Aurelija, et al.
Publicado: (2017)

Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles
por: Labriffe, Marc, et al.
Publicado: (2022)

Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects
por: Zha, Jiuhong, et al.
Publicado: (2022)

1383. Everolimus is Associated with an Increased Risk of Tuberculosis in Solid-Organ Transplant Recipients
por: Sun, Hsin-Yun, et al.
Publicado: (2019)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers()
por: Li, Kun-Yan, et al.
Publicado: (2014)

Tolerance and Pharmacokinetics of Recombinant Human Endostatin Administered as Single-Dose or Multiple-Dose Infusions in Patients With Advanced Solid Tumors: A Phase I Clinical Trial
por: Wang, Xu, et al.
Publicado: (2021)

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors
por: Berardi, Rossana, et al.
Publicado: (2017)

Confirmatory Composite Analysis
por: Schuberth, Florian, et al.
Publicado: (2018)

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling
por: Menzel, Karsten, et al.
Publicado: (2023)

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
por: Kümler, I., et al.
Publicado: (2018)

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers
por: Starks, David, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n6nthjhc87mkjftkciaf0nvp8u